Board of Directors
As the chairman and an independent non-executive director of Vivasure Medical, Dr Bernard Collins brings a wealth of business experience. He serves on the Board of Directors of several U.S. and Irish life-science companies. Prior to forming Lifemed, his consultancy company, Dr Collins served for 10 years as Vice President of International Operations at Boston Scientific Corporation and before this held senior executive positions in life-science companies including Baxter Corporation. His general management experience in the medical device and health care industry spans start-ups, turnarounds, leveraged buyouts and IPOs for both large and small businesses.
Dr Collins holds a BA Honors in Applied Industrial Psychology/Business from University College Cork, Ireland and an honorary Doctorate in Law from the National University of Ireland Galway. He is a recipient of the prestigious RDS Gold Medal for Industry in recognition of his extraordinary contribution to the development of the biomedical industry in Ireland.
Ger has over 25 years international business and company management experience with 18 years in Medtech. Previously, he worked in the USA with Ciba Geigy Corporation in engineering polymer R&D, operations and technical marketing and with Boston Scientific in the USA and Ireland in production and program management for the Vascular division. While with Boston, he was responsible for managing the transfer of over 25 stent and balloon product lines into the Galway manufacturing facility from around the world, and played a key role in the integration and manufacturing of the Schneider products into Galway.
He co-founded and was the CEO of Zerusa Limited, where he led the development and commercialisation of its hemostasis product in the EU and USA and positioned the company for acquisition by Vascular Solutions.
Barbara Castellano is a partner in Panakès Partners. She has more than 20 years of experience in Medtech, in particular in Cardiovascular, having held corporate senior positions at Sorin (now Livanova) and CID Cardiovascular (now Alvimedica).
By leading strategic marketing, business development, clinical, quality and regulatory departments, Barbara developed and brought innovative cardiovascular technologies to the market. More recently, as CEO of the advisory firm TechWald SpA, she has developed strong experience in the Medtech startup world, successfully raising over €15m in venture capital funding for innovative European and Israeli medical technology companies.
Barbara holds a degree in Medicinal Chemistry and an Executive MBA (both magna cum laude) from SDA Bocconi in Milan.
Robert (Chip) Hance is the former CEO of Creganna Medical, an Ireland-based medical device company with over 2,000 employees worldwide that was acquired by TE Connectivity in 2016. In 2012-13, Chip was an Entrepreneur-in-Residence at the Center for Devices and Radiological Health within the United States Food and Drug Administration (FDA), where he co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.
Prior to his FDA experience, Chip was most recently President of Abbott Vascular, the cardiovascular device division of Abbott. Over a decade in interventional cardiology at Abbott Vascular, he led the organization to global leadership in the drug-eluting stent market through the launch of Xience in the U.S., Japan and China. Chip also led the development and CE marking of Absorb, a bioabsorbable scaffold for the treatment of coronary disease and the acquisition and international expansion of Mitraclip, a percutaneous mitral valve repair device.
Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.
Justin Lynch is a partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years of experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science. Justin has a particular interest in the medical device sector and led the firm's investments in Vivasure Medical and in Neuravi where he also serves as a board member.
Anne Portwich, Ph.D, is a Partner of LSP (Life Sciences Partners), one of Europe’s largest and most experienced healthcare investment firms. Within LSP, Anne is focusing mainly on investments in medical technology companies, being part of the team investing the LSP Health Economics Fund. Anne currently serves on the supervisory boards of Mint Solutions (Netherlands), Neuravi (Ireland), ViCentra (Netherlands) and Vivasure Medical (Ireland). Previous board positions include Sapiens Steering Brain Stimulation (acquired by Medtronic in 2014), ActoGeniX (acquired by Intrexon in 2015) and Nexstim (IPO in 2014). Prior to joining LSP, Anne was a scientist and project leader at OctoPlus, a Dutch company offering advanced research services to pharmaceutical and biotechnology companies. She obtained an M.Sc. in biochemistry from the University of Hanover and received her Ph.D from the Max Planck-Society.
Dr. Mark Redshaw is as an investment manager at Evonik Venture Capital GmbH. Previously, he held senior international positions within the health and nutrition business of Evonik. His roles have included responsibility for service differentiation, developing environmental, economic and societal sustainability in business, and Head of Evonik Animal Nutrition Services. Mark's prior roles have included implementation of global CRM, management, pricing and account management systems as well as business operations roles in Africa and the Middle East. Mark studied Agriculture at the University of Reading and received a Ph.D. from the University of Nottingham.